Acta Pharmaceutica Sinica B-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1015122, encodeId=c16f101512290, content=偏重的研究方向：药理学 经验分享：刚投了一篇，到今天有一周了，还在with editior，不知道结果咋样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=ms3000000025379696, createdTime=Mon Sep 06 16:55:23 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887486, encodeId=6eb388e486d9, content=已投期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Tue Sep 22 21:25:59 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883337, encodeId=353788333ef3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：国内药学顶级期刊，双月刊，投稿多，所以处理起来很慢，四个审稿人问了30个问题。<a href='/topic/show?id=18d18e91434' target=_blank style='color:#2F92EE;'>#药理学与细胞分子生物学#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=87914, encryptionId=18d18e91434, topicName=药理学与细胞分子生物学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0712297263, createdName=121fbcdem21(暂无昵称), createdTime=Mon Sep 07 16:07:39 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104697, encodeId=da94210469ea6, content=一审一个月，修回后很快under review，现在快两个月了状态都没变，还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0c08110505, createdName=ms6000000900212273, createdTime=Wed Dec 07 09:39:03 CST 2022, time=2022-12-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2093129, encodeId=65ac2093129ac, content=投稿命中率:5.0 偏重的研究方向：药理学 经验分享：9月底投的综述，1号还是2号开始with editor，过了几天status data变了一下，状态不变。课题组之前投的research article被拒非常快，都没有超过五天的，最快的一次都没满24h...我是不是可以理解有希望送审..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Tue Oct 11 15:36:33 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204379, encodeId=2d2f12043e9d1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：要求很严格，审稿很细节, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=223b5709725, createdName=ms5000000604744412, createdTime=Sun Mar 20 17:22:42 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185648, encodeId=6df5118564873, content=关系圈杂志，战友们不要浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Tue Jan 18 15:59:12 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589905, encodeId=6c2f589905cd, content=请问下，怎样判断送审了呢？这个期刊是不是很慢156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, beContent=156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJqJyv2w5VEn3QCI0n7qJAmEbhEelgjhGibgbL5OY5J8e2I09IePMFS6VD97h3SFRSTvjibh5GqHicFA/132, createdBy=42375318535, createdName=Blake , createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588409, encodeId=0aed58840942, content=请问你投的时候所有作者都确认了吗？156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, beContent=156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fdc5164025, createdName=438044838_57546993, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=)]

2021-09-06 ms3000000025379696

偏重的研究方向：药理学
经验分享：刚投了一篇，到今天有一周了，还在with editior，不知道结果咋样呢？

176 23

展开23条回复

[GetPortalCommentsPageByObjectIdResponse(id=1015122, encodeId=c16f101512290, content=偏重的研究方向：药理学 经验分享：刚投了一篇，到今天有一周了，还在with editior，不知道结果咋样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=ms3000000025379696, createdTime=Mon Sep 06 16:55:23 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887486, encodeId=6eb388e486d9, content=已投期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Tue Sep 22 21:25:59 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883337, encodeId=353788333ef3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：国内药学顶级期刊，双月刊，投稿多，所以处理起来很慢，四个审稿人问了30个问题。<a href='/topic/show?id=18d18e91434' target=_blank style='color:#2F92EE;'>#药理学与细胞分子生物学#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=87914, encryptionId=18d18e91434, topicName=药理学与细胞分子生物学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0712297263, createdName=121fbcdem21(暂无昵称), createdTime=Mon Sep 07 16:07:39 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104697, encodeId=da94210469ea6, content=一审一个月，修回后很快under review，现在快两个月了状态都没变，还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0c08110505, createdName=ms6000000900212273, createdTime=Wed Dec 07 09:39:03 CST 2022, time=2022-12-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2093129, encodeId=65ac2093129ac, content=投稿命中率:5.0 偏重的研究方向：药理学 经验分享：9月底投的综述，1号还是2号开始with editor，过了几天status data变了一下，状态不变。课题组之前投的research article被拒非常快，都没有超过五天的，最快的一次都没满24h...我是不是可以理解有希望送审..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Tue Oct 11 15:36:33 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204379, encodeId=2d2f12043e9d1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：要求很严格，审稿很细节, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=223b5709725, createdName=ms5000000604744412, createdTime=Sun Mar 20 17:22:42 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185648, encodeId=6df5118564873, content=关系圈杂志，战友们不要浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Tue Jan 18 15:59:12 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589905, encodeId=6c2f589905cd, content=请问下，怎样判断送审了呢？这个期刊是不是很慢156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, beContent=156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJqJyv2w5VEn3QCI0n7qJAmEbhEelgjhGibgbL5OY5J8e2I09IePMFS6VD97h3SFRSTvjibh5GqHicFA/132, createdBy=42375318535, createdName=Blake , createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588409, encodeId=0aed58840942, content=请问你投的时候所有作者都确认了吗？156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, beContent=156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fdc5164025, createdName=438044838_57546993, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=)]

2020-09-22 a201061519

已投期待中

162 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=1015122, encodeId=c16f101512290, content=偏重的研究方向：药理学 经验分享：刚投了一篇，到今天有一周了，还在with editior，不知道结果咋样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=ms3000000025379696, createdTime=Mon Sep 06 16:55:23 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887486, encodeId=6eb388e486d9, content=已投期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Tue Sep 22 21:25:59 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883337, encodeId=353788333ef3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：国内药学顶级期刊，双月刊，投稿多，所以处理起来很慢，四个审稿人问了30个问题。<a href='/topic/show?id=18d18e91434' target=_blank style='color:#2F92EE;'>#药理学与细胞分子生物学#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=87914, encryptionId=18d18e91434, topicName=药理学与细胞分子生物学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0712297263, createdName=121fbcdem21(暂无昵称), createdTime=Mon Sep 07 16:07:39 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104697, encodeId=da94210469ea6, content=一审一个月，修回后很快under review，现在快两个月了状态都没变，还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0c08110505, createdName=ms6000000900212273, createdTime=Wed Dec 07 09:39:03 CST 2022, time=2022-12-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2093129, encodeId=65ac2093129ac, content=投稿命中率:5.0 偏重的研究方向：药理学 经验分享：9月底投的综述，1号还是2号开始with editor，过了几天status data变了一下，状态不变。课题组之前投的research article被拒非常快，都没有超过五天的，最快的一次都没满24h...我是不是可以理解有希望送审..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Tue Oct 11 15:36:33 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204379, encodeId=2d2f12043e9d1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：要求很严格，审稿很细节, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=223b5709725, createdName=ms5000000604744412, createdTime=Sun Mar 20 17:22:42 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185648, encodeId=6df5118564873, content=关系圈杂志，战友们不要浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Tue Jan 18 15:59:12 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589905, encodeId=6c2f589905cd, content=请问下，怎样判断送审了呢？这个期刊是不是很慢156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, beContent=156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJqJyv2w5VEn3QCI0n7qJAmEbhEelgjhGibgbL5OY5J8e2I09IePMFS6VD97h3SFRSTvjibh5GqHicFA/132, createdBy=42375318535, createdName=Blake , createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588409, encodeId=0aed58840942, content=请问你投的时候所有作者都确认了吗？156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, beContent=156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fdc5164025, createdName=438044838_57546993, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=)]

2020-09-07 121fbcdem21(暂无昵称)

审稿速度:3.0 | 投稿命中率:50.0
经验分享：国内药学顶级期刊，双月刊，投稿多，所以处理起来很慢，四个审稿人问了30个问题。#药理学与细胞分子生物学#

202 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=1015122, encodeId=c16f101512290, content=偏重的研究方向：药理学 经验分享：刚投了一篇，到今天有一周了，还在with editior，不知道结果咋样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=ms3000000025379696, createdTime=Mon Sep 06 16:55:23 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887486, encodeId=6eb388e486d9, content=已投期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Tue Sep 22 21:25:59 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883337, encodeId=353788333ef3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：国内药学顶级期刊，双月刊，投稿多，所以处理起来很慢，四个审稿人问了30个问题。<a href='/topic/show?id=18d18e91434' target=_blank style='color:#2F92EE;'>#药理学与细胞分子生物学#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=87914, encryptionId=18d18e91434, topicName=药理学与细胞分子生物学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0712297263, createdName=121fbcdem21(暂无昵称), createdTime=Mon Sep 07 16:07:39 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104697, encodeId=da94210469ea6, content=一审一个月，修回后很快under review，现在快两个月了状态都没变，还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0c08110505, createdName=ms6000000900212273, createdTime=Wed Dec 07 09:39:03 CST 2022, time=2022-12-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2093129, encodeId=65ac2093129ac, content=投稿命中率:5.0 偏重的研究方向：药理学 经验分享：9月底投的综述，1号还是2号开始with editor，过了几天status data变了一下，状态不变。课题组之前投的research article被拒非常快，都没有超过五天的，最快的一次都没满24h...我是不是可以理解有希望送审..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Tue Oct 11 15:36:33 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204379, encodeId=2d2f12043e9d1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：要求很严格，审稿很细节, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=223b5709725, createdName=ms5000000604744412, createdTime=Sun Mar 20 17:22:42 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185648, encodeId=6df5118564873, content=关系圈杂志，战友们不要浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Tue Jan 18 15:59:12 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589905, encodeId=6c2f589905cd, content=请问下，怎样判断送审了呢？这个期刊是不是很慢156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, beContent=156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJqJyv2w5VEn3QCI0n7qJAmEbhEelgjhGibgbL5OY5J8e2I09IePMFS6VD97h3SFRSTvjibh5GqHicFA/132, createdBy=42375318535, createdName=Blake , createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588409, encodeId=0aed58840942, content=请问你投的时候所有作者都确认了吗？156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, beContent=156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fdc5164025, createdName=438044838_57546993, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=)]

2022-12-07 ms6000000900212273 来自江苏省

一审一个月，修回后很快under review，现在快两个月了状态都没变，还要多久啊

50 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1015122, encodeId=c16f101512290, content=偏重的研究方向：药理学 经验分享：刚投了一篇，到今天有一周了，还在with editior，不知道结果咋样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=ms3000000025379696, createdTime=Mon Sep 06 16:55:23 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887486, encodeId=6eb388e486d9, content=已投期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Tue Sep 22 21:25:59 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883337, encodeId=353788333ef3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：国内药学顶级期刊，双月刊，投稿多，所以处理起来很慢，四个审稿人问了30个问题。<a href='/topic/show?id=18d18e91434' target=_blank style='color:#2F92EE;'>#药理学与细胞分子生物学#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=87914, encryptionId=18d18e91434, topicName=药理学与细胞分子生物学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0712297263, createdName=121fbcdem21(暂无昵称), createdTime=Mon Sep 07 16:07:39 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104697, encodeId=da94210469ea6, content=一审一个月，修回后很快under review，现在快两个月了状态都没变，还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0c08110505, createdName=ms6000000900212273, createdTime=Wed Dec 07 09:39:03 CST 2022, time=2022-12-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2093129, encodeId=65ac2093129ac, content=投稿命中率:5.0 偏重的研究方向：药理学 经验分享：9月底投的综述，1号还是2号开始with editor，过了几天status data变了一下，状态不变。课题组之前投的research article被拒非常快，都没有超过五天的，最快的一次都没满24h...我是不是可以理解有希望送审..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Tue Oct 11 15:36:33 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204379, encodeId=2d2f12043e9d1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：要求很严格，审稿很细节, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=223b5709725, createdName=ms5000000604744412, createdTime=Sun Mar 20 17:22:42 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185648, encodeId=6df5118564873, content=关系圈杂志，战友们不要浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Tue Jan 18 15:59:12 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589905, encodeId=6c2f589905cd, content=请问下，怎样判断送审了呢？这个期刊是不是很慢156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, beContent=156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJqJyv2w5VEn3QCI0n7qJAmEbhEelgjhGibgbL5OY5J8e2I09IePMFS6VD97h3SFRSTvjibh5GqHicFA/132, createdBy=42375318535, createdName=Blake , createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588409, encodeId=0aed58840942, content=请问你投的时候所有作者都确认了吗？156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, beContent=156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fdc5164025, createdName=438044838_57546993, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=)]

2022-10-11 ms6000001594127539

投稿命中率:5.0
偏重的研究方向：药理学
经验分享：9月底投的综述，1号还是2号开始with editor，过了几天status data变了一下，状态不变。课题组之前投的research article被拒非常快，都没有超过五天的，最快的一次都没满24h...我是不是可以理解有希望送审...

48 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1015122, encodeId=c16f101512290, content=偏重的研究方向：药理学 经验分享：刚投了一篇，到今天有一周了，还在with editior，不知道结果咋样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=ms3000000025379696, createdTime=Mon Sep 06 16:55:23 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887486, encodeId=6eb388e486d9, content=已投期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Tue Sep 22 21:25:59 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883337, encodeId=353788333ef3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：国内药学顶级期刊，双月刊，投稿多，所以处理起来很慢，四个审稿人问了30个问题。<a href='/topic/show?id=18d18e91434' target=_blank style='color:#2F92EE;'>#药理学与细胞分子生物学#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=87914, encryptionId=18d18e91434, topicName=药理学与细胞分子生物学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0712297263, createdName=121fbcdem21(暂无昵称), createdTime=Mon Sep 07 16:07:39 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104697, encodeId=da94210469ea6, content=一审一个月，修回后很快under review，现在快两个月了状态都没变，还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0c08110505, createdName=ms6000000900212273, createdTime=Wed Dec 07 09:39:03 CST 2022, time=2022-12-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2093129, encodeId=65ac2093129ac, content=投稿命中率:5.0 偏重的研究方向：药理学 经验分享：9月底投的综述，1号还是2号开始with editor，过了几天status data变了一下，状态不变。课题组之前投的research article被拒非常快，都没有超过五天的，最快的一次都没满24h...我是不是可以理解有希望送审..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Tue Oct 11 15:36:33 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204379, encodeId=2d2f12043e9d1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：要求很严格，审稿很细节, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=223b5709725, createdName=ms5000000604744412, createdTime=Sun Mar 20 17:22:42 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185648, encodeId=6df5118564873, content=关系圈杂志，战友们不要浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Tue Jan 18 15:59:12 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589905, encodeId=6c2f589905cd, content=请问下，怎样判断送审了呢？这个期刊是不是很慢156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, beContent=156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJqJyv2w5VEn3QCI0n7qJAmEbhEelgjhGibgbL5OY5J8e2I09IePMFS6VD97h3SFRSTvjibh5GqHicFA/132, createdBy=42375318535, createdName=Blake , createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588409, encodeId=0aed58840942, content=请问你投的时候所有作者都确认了吗？156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, beContent=156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fdc5164025, createdName=438044838_57546993, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=)]

2022-10-17 ms9000000615443695

为什么他们Decision in Process也很长时间啊！！！

39 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1015122, encodeId=c16f101512290, content=偏重的研究方向：药理学 经验分享：刚投了一篇，到今天有一周了，还在with editior，不知道结果咋样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=ms3000000025379696, createdTime=Mon Sep 06 16:55:23 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887486, encodeId=6eb388e486d9, content=已投期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Tue Sep 22 21:25:59 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883337, encodeId=353788333ef3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：国内药学顶级期刊，双月刊，投稿多，所以处理起来很慢，四个审稿人问了30个问题。<a href='/topic/show?id=18d18e91434' target=_blank style='color:#2F92EE;'>#药理学与细胞分子生物学#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=87914, encryptionId=18d18e91434, topicName=药理学与细胞分子生物学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0712297263, createdName=121fbcdem21(暂无昵称), createdTime=Mon Sep 07 16:07:39 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104697, encodeId=da94210469ea6, content=一审一个月，修回后很快under review，现在快两个月了状态都没变，还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0c08110505, createdName=ms6000000900212273, createdTime=Wed Dec 07 09:39:03 CST 2022, time=2022-12-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2093129, encodeId=65ac2093129ac, content=投稿命中率:5.0 偏重的研究方向：药理学 经验分享：9月底投的综述，1号还是2号开始with editor，过了几天status data变了一下，状态不变。课题组之前投的research article被拒非常快，都没有超过五天的，最快的一次都没满24h...我是不是可以理解有希望送审..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Tue Oct 11 15:36:33 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204379, encodeId=2d2f12043e9d1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：要求很严格，审稿很细节, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=223b5709725, createdName=ms5000000604744412, createdTime=Sun Mar 20 17:22:42 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185648, encodeId=6df5118564873, content=关系圈杂志，战友们不要浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Tue Jan 18 15:59:12 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589905, encodeId=6c2f589905cd, content=请问下，怎样判断送审了呢？这个期刊是不是很慢156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, beContent=156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJqJyv2w5VEn3QCI0n7qJAmEbhEelgjhGibgbL5OY5J8e2I09IePMFS6VD97h3SFRSTvjibh5GqHicFA/132, createdBy=42375318535, createdName=Blake , createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588409, encodeId=0aed58840942, content=请问你投的时候所有作者都确认了吗？156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, beContent=156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fdc5164025, createdName=438044838_57546993, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=)]

2022-03-20 ms5000000604744412

审稿速度:2.0 | 投稿命中率:25.0
经验分享：要求很严格，审稿很细节

117 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1015122, encodeId=c16f101512290, content=偏重的研究方向：药理学 经验分享：刚投了一篇，到今天有一周了，还在with editior，不知道结果咋样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=ms3000000025379696, createdTime=Mon Sep 06 16:55:23 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887486, encodeId=6eb388e486d9, content=已投期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Tue Sep 22 21:25:59 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883337, encodeId=353788333ef3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：国内药学顶级期刊，双月刊，投稿多，所以处理起来很慢，四个审稿人问了30个问题。<a href='/topic/show?id=18d18e91434' target=_blank style='color:#2F92EE;'>#药理学与细胞分子生物学#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=87914, encryptionId=18d18e91434, topicName=药理学与细胞分子生物学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0712297263, createdName=121fbcdem21(暂无昵称), createdTime=Mon Sep 07 16:07:39 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104697, encodeId=da94210469ea6, content=一审一个月，修回后很快under review，现在快两个月了状态都没变，还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0c08110505, createdName=ms6000000900212273, createdTime=Wed Dec 07 09:39:03 CST 2022, time=2022-12-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2093129, encodeId=65ac2093129ac, content=投稿命中率:5.0 偏重的研究方向：药理学 经验分享：9月底投的综述，1号还是2号开始with editor，过了几天status data变了一下，状态不变。课题组之前投的research article被拒非常快，都没有超过五天的，最快的一次都没满24h...我是不是可以理解有希望送审..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Tue Oct 11 15:36:33 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204379, encodeId=2d2f12043e9d1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：要求很严格，审稿很细节, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=223b5709725, createdName=ms5000000604744412, createdTime=Sun Mar 20 17:22:42 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185648, encodeId=6df5118564873, content=关系圈杂志，战友们不要浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Tue Jan 18 15:59:12 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589905, encodeId=6c2f589905cd, content=请问下，怎样判断送审了呢？这个期刊是不是很慢156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, beContent=156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJqJyv2w5VEn3QCI0n7qJAmEbhEelgjhGibgbL5OY5J8e2I09IePMFS6VD97h3SFRSTvjibh5GqHicFA/132, createdBy=42375318535, createdName=Blake , createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588409, encodeId=0aed58840942, content=请问你投的时候所有作者都确认了吗？156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, beContent=156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fdc5164025, createdName=438044838_57546993, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=)]

2022-01-18 丿柚子

关系圈杂志，战友们不要浪费时间了。

166 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1015122, encodeId=c16f101512290, content=偏重的研究方向：药理学 经验分享：刚投了一篇，到今天有一周了，还在with editior，不知道结果咋样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=ms3000000025379696, createdTime=Mon Sep 06 16:55:23 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887486, encodeId=6eb388e486d9, content=已投期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Tue Sep 22 21:25:59 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883337, encodeId=353788333ef3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：国内药学顶级期刊，双月刊，投稿多，所以处理起来很慢，四个审稿人问了30个问题。<a href='/topic/show?id=18d18e91434' target=_blank style='color:#2F92EE;'>#药理学与细胞分子生物学#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=87914, encryptionId=18d18e91434, topicName=药理学与细胞分子生物学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0712297263, createdName=121fbcdem21(暂无昵称), createdTime=Mon Sep 07 16:07:39 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104697, encodeId=da94210469ea6, content=一审一个月，修回后很快under review，现在快两个月了状态都没变，还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0c08110505, createdName=ms6000000900212273, createdTime=Wed Dec 07 09:39:03 CST 2022, time=2022-12-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2093129, encodeId=65ac2093129ac, content=投稿命中率:5.0 偏重的研究方向：药理学 经验分享：9月底投的综述，1号还是2号开始with editor，过了几天status data变了一下，状态不变。课题组之前投的research article被拒非常快，都没有超过五天的，最快的一次都没满24h...我是不是可以理解有希望送审..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Tue Oct 11 15:36:33 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204379, encodeId=2d2f12043e9d1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：要求很严格，审稿很细节, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=223b5709725, createdName=ms5000000604744412, createdTime=Sun Mar 20 17:22:42 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185648, encodeId=6df5118564873, content=关系圈杂志，战友们不要浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Tue Jan 18 15:59:12 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589905, encodeId=6c2f589905cd, content=请问下，怎样判断送审了呢？这个期刊是不是很慢156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, beContent=156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJqJyv2w5VEn3QCI0n7qJAmEbhEelgjhGibgbL5OY5J8e2I09IePMFS6VD97h3SFRSTvjibh5GqHicFA/132, createdBy=42375318535, createdName=Blake , createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588409, encodeId=0aed58840942, content=请问你投的时候所有作者都确认了吗？156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, beContent=156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fdc5164025, createdName=438044838_57546993, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=)]

2020-04-29 Blake

请问下，怎样判断送审了呢？这个期刊是不是很慢156****6969暂无昵称 2020-04-08 00:00:00 发表:
没有

156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有

177 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1015122, encodeId=c16f101512290, content=偏重的研究方向：药理学 经验分享：刚投了一篇，到今天有一周了，还在with editior，不知道结果咋样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=ms3000000025379696, createdTime=Mon Sep 06 16:55:23 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887486, encodeId=6eb388e486d9, content=已投期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Tue Sep 22 21:25:59 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883337, encodeId=353788333ef3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：国内药学顶级期刊，双月刊，投稿多，所以处理起来很慢，四个审稿人问了30个问题。<a href='/topic/show?id=18d18e91434' target=_blank style='color:#2F92EE;'>#药理学与细胞分子生物学#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=87914, encryptionId=18d18e91434, topicName=药理学与细胞分子生物学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0712297263, createdName=121fbcdem21(暂无昵称), createdTime=Mon Sep 07 16:07:39 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104697, encodeId=da94210469ea6, content=一审一个月，修回后很快under review，现在快两个月了状态都没变，还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0c08110505, createdName=ms6000000900212273, createdTime=Wed Dec 07 09:39:03 CST 2022, time=2022-12-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2093129, encodeId=65ac2093129ac, content=投稿命中率:5.0 偏重的研究方向：药理学 经验分享：9月底投的综述，1号还是2号开始with editor，过了几天status data变了一下，状态不变。课题组之前投的research article被拒非常快，都没有超过五天的，最快的一次都没满24h...我是不是可以理解有希望送审..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Tue Oct 11 15:36:33 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204379, encodeId=2d2f12043e9d1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：要求很严格，审稿很细节, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=223b5709725, createdName=ms5000000604744412, createdTime=Sun Mar 20 17:22:42 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185648, encodeId=6df5118564873, content=关系圈杂志，战友们不要浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Tue Jan 18 15:59:12 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589905, encodeId=6c2f589905cd, content=请问下，怎样判断送审了呢？这个期刊是不是很慢156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, beContent=156****6969暂无昵称 2020-04-08 00:00:00 发表: 没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJqJyv2w5VEn3QCI0n7qJAmEbhEelgjhGibgbL5OY5J8e2I09IePMFS6VD97h3SFRSTvjibh5GqHicFA/132, createdBy=42375318535, createdName=Blake , createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588409, encodeId=0aed58840942, content=请问你投的时候所有作者都确认了吗？156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, beContent=156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fdc5164025, createdName=438044838_57546993, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=)]

2020-04-08 438044838_57546993

请问你投的时候所有作者都确认了吗？156****6969暂无昵称 2020-02-02 00:00:00 发表:
请问需要作者全部确认吗

156****6969暂无昵称 2020-02-02 00:00:00 发表: 请问需要作者全部确认吗

206 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务